# Grażyna Rydzewska

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/grazyna-rydzewska/

## Facts

| Field | Value |
| --- | --- |
| Citations | 3,548 |
| Field | Inflammatory Bowel Disease |
| h-index | 29 |
| i10-index | 84 |
| Last Known Institution | Jan Kochanowski University |
| OpenAlex ID | https://openalex.org/A5040820837 |
| ORCID iD | 0000-0002-1267-7620 |
| Works | 329 |

## Researcher papers

- [Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn's disease: a multicentre, randomised, double-blind, parallel-group, phase 3b trial](https://scholariq.org/papers/ustekinumab-versus-adalimumab-for-induction-and-maintenance-therapy-in-biologic/)
- [Deep Remission at 1 Year Prevents Progression of Early Crohn’s Disease](https://scholariq.org/papers/deep-remission-at-1-year-prevents-progression-of-early-crohn-s-disease/)
- [Guselkumab plus golimumab combination therapy versus guselkumab or golimumab monotherapy in patients with ulcerative colitis (VEGA): a randomised, double-blind, controlled, phase 2, proof-of-concept trial](https://scholariq.org/papers/guselkumab-plus-golimumab-combination-therapy-versus-guselkumab-or-golimumab/)
- [Guselkumab in Patients With Moderately to Severely Active Ulcerative Colitis: QUASAR Phase 2b Induction Study](https://scholariq.org/papers/guselkumab-in-patients-with-moderately-to-severely-active-ulcerative-colitis/)
- [Etrolizumab as induction and maintenance therapy for ulcerative colitis in patients previously treated with tumour necrosis factor inhibitors (HICKORY): a phase 3, randomised, controlled trial](https://scholariq.org/papers/etrolizumab-as-induction-and-maintenance-therapy-for-ulcerative-colitis-in/)
- [The Results of Severe Acute Pancreatitis Treatment With Continuous Regional Arterial Infusion of Protease Inhibitor and Antibiotic](https://scholariq.org/papers/the-results-of-severe-acute-pancreatitis-treatment-with-continuous-regional/)
- [Etrolizumab as induction and maintenance therapy in patients with moderately to severely active Crohn's disease (BERGAMOT): a randomised, placebo-controlled, double-blind, phase 3 trial](https://scholariq.org/papers/etrolizumab-as-induction-and-maintenance-therapy-in-patients-with-moderately-to/)
- [Clinical Effects of a Topically Applied Toll-like Receptor 9 Agonist in Active Moderate-to-Severe Ulcerative Colitis](https://scholariq.org/papers/clinical-effects-of-a-topically-applied-toll-like-receptor-9-agonist-in-active/)
- [Zalecenia ogólne dotyczące postępowania w nowotworach neuroendokrynnych układu pokarmowego (rekomendowane przez Polską Sieć Guzów Neuroendokrynnych)](https://scholariq.org/papers/zalecenia-ogolne-dotyczace-postepowania-w-nowotworach-neuroendokrynnych-uk-adu/)
- [Effectiveness of Crohn’s Disease Exclusion Diet for Induction of Remission in Crohn’s Disease Adult Patients](https://scholariq.org/papers/effectiveness-of-crohn-s-disease-exclusion-diet-for-induction-of-remission-in/)
- [Irritable bowel syndrome following COVID-19: underestimated consequence of infection with SARS-CoV-2](https://scholariq.org/papers/irritable-bowel-syndrome-following-covid-19-underestimated-consequence-of/)

## Researcher topics

- [Inflammatory Bowel Disease](https://scholariq.org/topics/inflammatory-bowel-disease/)
- [Pancreatitis Pathology and Treatment](https://scholariq.org/topics/pancreatitis-pathology-and-treatment/)
- [Microscopic Colitis](https://scholariq.org/topics/microscopic-colitis/)
- [Gastrointestinal motility and disorders](https://scholariq.org/topics/gastrointestinal-motility-and-disorders/)
- [Pancreatic and Hepatic Oncology Research](https://scholariq.org/topics/pancreatic-and-hepatic-oncology-research/)

## Researcher university

- [Jan Kochanowski University](https://scholariq.org/institutions/jan-kochanowski-university/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.